David A. Cheresh

David A. Cheresh

Auto-generated profile, based on publicly available information

David A. Cheresh

Department of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine, University of California, San Diego, San Diego, California

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2001 in Current Opinion in Cell Biology
Verified
Journal Article
Closed access
BEBrian Eliceiri
Brian Eliceiri
DCDavid A Cheresh
David A Cheresh

29 May 2018 in Cell Discovery
Verified
Journal Article
Open access
PDF file
HWHuawei Wang
Huawei Wang
JLJohn Lapek
John Lapek
KFKen Fujimura
Ken Fujimura
JSJan Strnadel
Jan Strnadel
BLBei Liu
Bei Liu
RKRichard L. Klemke
Richard L. Klemke
PEAK1 is a newly described tyrosine kinase and scaffold protein that transmits integrin-mediated extracellular matrix (ECM) signals to facilitate cell movement and growth. While aberrant expression of PEAK1 has been linked to cancer progression, its normal physiological role in vertebrate biology is not known. Here we provide evidence that PEAK1 plays a central role in orchestrating new vessel formation in vertebrates. Deletion of the PEAK1 gene in zebrafish, mice, and human endothelial cells (ECs) induced severe defects in new blood vessel formation due to deficiencies in EC proliferation, survival, and migration. Gene transcriptional and proteomic analyses of PEAK1-deficient ECs revealed a significant loss of vascular endothelial growth factor receptor 2 (VEGFR2) mRNA and protein expression, as well as downstream signaling to its effectors, ERK, Akt, and Src kinase. PEAK1 regulates VEGFR2 expression by binding to and increasing the protein stability of the transcription factor GATA-binding protein 2 (GATA2), which controls VEGFR2 transcription. Importantly, PEAK1-GATA2-dependent VEGFR2 expression is mediated by EC adhesion to the ECM and is required for breast cancer-induced new vessel formation in mice. Also, elevated expression of PEAK1 and VEGFR2 mRNA are highly correlated in many human cancers including breast cancer. Together, our findings reveal a novel PEAK1-GATA2-VEGFR2 signaling axis that integrates cell adhesion and growth factor cues from the extracellular environment necessary for new vessel formation during vertebrate development and cancer.

16 January 2023 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
CWChengsheng Wu
Chengsheng Wu
TRTaha Rakhshandehroo
Taha Rakhshandehroo
HWHiromi I. Wettersten
Hiromi I. Wettersten
ACAlejandro Campos
Alejandro Campos
TSTami von Schalscha
Tami von Schalscha
DCDavid A. Cheresh
David A. Cheresh

8 April 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
ANArin Nam
Arin Nam
SJShashi Jain
Shashi Jain
CWChengsheng Wu
Chengsheng Wu
ACAlejandro Campos
Alejandro Campos
RSRyan M. Shepard
Ryan M. Shepard
DCDavid A. Cheresh
David A. Cheresh
Cancer stem/tumor-initiating cells display stress tolerance and metabolic flexibility to survive in a harsh environment with limited nutrient and oxygen availability. The molecular mechanisms underlying this phenomenon could provide targets to prevent metabolic adaptation and halt cancer progression. Here, we showed in cultured cells and live human surgical biopsies of non–small cell lung cancer that nutrient stress drives the expression of the epithelial cancer stem cell marker integrin αvβ3 via upregulation of the β3 subunit, resulting in a metabolic reprogramming cascade that allows tumor cells to thrive despite a nutrient-limiting environment. Although nutrient deprivation is known to promote acute, yet transient, activation of the stress sensor AMP-activated protein kinase (AMPK), stress-induced αvβ3 expression via Src activation unexpectedly led to secondary and sustained AMPK activation. This resulted in the nuclear localization of peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC1α) and upregulation of glutamine metabolism, the tricarboxylic acid cycle, and oxidative phosphorylation. Pharmacological or genetic targeting of this axis prevented lung cancer cells from evading the effects of nutrient stress, thereby blocking tumor initiation in mice following orthotopic implantation of lung cancer cells. These findings reveal a molecular pathway driven by nutrient stress that results in cancer stem cell reprogramming to promote metabolic flexibility and tumor initiation. Significance: Upregulation of integrin αvβ3, a cancer stem cell marker, in response to nutrient stress activates sustained AMPK/PGC1α signaling that induces metabolic reprogramming in lung cancer cells to support their survival. See related commentary by Rainero, p. 1543

1 January 2025 in Cancer Research Communications
Verified
Journal Article
Open access
CWChengsheng Wu
Chengsheng Wu
TSTami Von Schalscha
Tami Von Schalscha
DSDiva Sansanwal
Diva Sansanwal
CQChen Qian
Chen Qian
QJQinlin Jiang
Qinlin Jiang
DCDavid A. Cheresh
David A. Cheresh
Cancer-associated fibroblasts (CAF) generate an extracellular matrix (ECM) which provides a repository for factors that promote pancreatic cancer progression. In this study, we establish that CAF contribution to pancreatic tumor initiation, i.e., stemness, depends on fibronectin (FN) as a scaffold required for assembly of a collagen-containing fibrotic ECM with a critical dependence on the FN-binding integrins, α5β1 and αvβ3. CAF matrix assembly can be prevented by knockdown of FN, integrin α5, or integrin β3 or by a bispecific antibody with dual recognition of α5β1 and αvβ3 that can also destabilize a preexisting matrix. In mice, the ability of CAFs to produce a stiff collagenous matrix and accelerate tumor initiation can be blocked by knockdown of FN or FN-binding integrins or systemic treatment with the α5β1/αvβ3 bispecific antibody. Together, these results reveal that dual targeting of the FN-binding integrins, α5β1 and αvβ3, can block the ability of CAFs and their matrix to enhance pancreatic cancer stemness and progression. Significance: Simultaneous targeting of two integrins that function as receptors for FN, a protumor ECM protein, can prevent fibroblasts from supporting the malignant behavior of pancreatic cancer cells.

22 July 2025 in Cell Reports
Verified
Journal Article
Open access
ACAlejandro D. Campos
Alejandro D. Campos
RSRyan M. Shepard
Ryan M. Shepard
ZOZachary Ortega
Zachary Ortega
IHIngrid Heumann
Ingrid Heumann
AWAnna E. Wilke
Anna E. Wilke
DCDavid A. Cheresh
David A. Cheresh
The signal transducer and activator of transcription 3 (STAT3) pathway drives pancreatic ductal adenocarcinoma (PDAC) progression by coordinating cellular responses to stress and inflammation. We perform ChIP-seq on hypoxia- or oncostatin-M-treated PDAC cells to identify sites at which phospho-STAT3 binds to regulate the expression of genes linked to poor survival. A top hit among these is ITGB3, which we show promotes PDAC initiation and progression. Single-cell transcriptomics reveal that ITGB3 expression is enriched in PDAC cells experiencing oxidative stress due to chemotherapy. Moreover, high ITGB3 expression positively correlates with STAT3 signaling, hypoxia, and the basal subtype. Mechanistically, chromatin accessibility at ITGB3 enhancers controls STAT3's ability to induce ITGB3 expression, illuminating a plastic regulatory mechanism modulating STAT3 activity. Leveraging this insight, we identify additional STAT3 target genes regulated similarly to ITGB3 to establish an 18-gene signature involved in adaptive responses and able to stratify survival outcomes. Collectively, these findings highlight a novel opportunity to stratify PDAC subpopulations for STAT3-targeted therapies.